Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122795
Filing Date
2024-11-07
Accepted
2024-11-07 07:18:20
Documents
57
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20240930.htm   iXBRL 10-Q 1607362
2 EX-31.1 cgem-ex31_1.htm EX-31.1 14018
3 EX-31.2 cgem-ex31_2.htm EX-31.2 13809
4 EX-32.1 cgem-ex32_1.htm EX-32.1 12705
  Complete submission text file 0000950170-24-122795.txt   6552227

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20240930.xsd EX-101.SCH 1104021
60 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20240930_htm.xml XML 947967
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813867811 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 241433162
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)